Literature DB >> 32471565

KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis.

Chenyue Zhang1, Chenxing Zhang2, Jia Li3, Haiyong Wang4.   

Abstract

Entities:  

Year:  2020        PMID: 32471565     DOI: 10.1016/j.jtho.2020.02.027

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

1.  KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials.

Authors:  Hongyuan Zhu; Daipeng Xie; Yunfang Yu; Lintong Yao; Bin Xu; Luyu Huang; Shaowei Wu; Fasheng Li; Yating Zheng; Xinyi Liu; Wenzhuan Xie; Mengli Huang; Hao Li; Shaopeng Zheng; Dongkun Zhang; Guibin Qiao; Lawrence W C Chan; Haiyu Zhou
Journal:  Front Oncol       Date:  2021-07-26       Impact factor: 6.244

2.  Multi-omics analysis identifies distinct subtypes with clinical relevance in lung adenocarcinoma harboring KEAP1/NFE2L2.

Authors:  Xiaodong Yang; Ming Li; Zhencong Chen; Xiaobin Fan; Liang Guo; Bo Jin; Yiwei Huang; Qun Wang; Liang Wu; Cheng Zhan
Journal:  J Cancer       Date:  2022-02-28       Impact factor: 4.207

3.  A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab.

Authors:  Jiamao Lin; Xiaohui Wang; Chenyue Zhang; Shuai Bu; Chenglong Zhao; Haiyong Wang
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.